Back to top
more

PetIQ (PETQ)

(Real Time Quote from BATS)

$30.88 USD

30.88
221,619

+0.01 (0.03%)

Updated Oct 7, 2024 02:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data

by Zacks Equity Research

Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.

SmileDirectClub (SDC) Reels Under Cyber Attack, Pandemic Woes

by Zacks Equity Research

SmileDirectClub (SDC) apprehends systems outage to have an adverse impact on its second-quarter revenues to the tune of approximately $10-$15 million.

Riya Anand headshot

Pandemic Boosts Animal Health Spending: 4 Stocks to Buy

by Riya Anand

Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.

Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.

Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake

by Zacks Equity Research

Boston Scientific (BSX) currently holds an equity stake of roughly 27%.

Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues

by Zacks Equity Research

Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.

OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal

by Zacks Equity Research

OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.

Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line

by Zacks Equity Research

Penumbra (PEN) to initiate commercialization of RED 62 Reperfusion Catheter post FDA clearance.

Medtronic (MDT) Reports First Surgery With Hugo RAS System (Revised)

by Zacks Equity Research

Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.

Medtronic (MDT) Reports First Surgery With Hugo RAS System

by Zacks Equity Research

Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.

Thermo Fisher (TMO) Invites Applications for Oncomine Program

by Zacks Equity Research

Thermo Fisher (TMO) to review research proposals eligible for the Oncomine Clinical Research Grant program.

NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry

by Zacks Equity Research

NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.

    Accuray's (ARAY) CyberKnife Gets Support From RayStation TPS

    by Zacks Equity Research

    Accuray (ARAY) introduces RayStation treatment planning support for CyberKnife Radiotherapy System and other radiation therapy devices.

    CVS Health (CVS) Introduces Changes in ExtraBucks Program

    by Zacks Equity Research

    CVS Health's (CVS) retail division to offer instant 2% ExtraBucks rewards on purchases through the ExtraCare Rewards loyalty program.

    Walgreens (WBA) Rolls Out Plan to Boost COVID-19 Vaccination

    by Zacks Equity Research

    Walgreens Boots' (WBA) U.S. pharmacy segment to extend pharmacy timings for COVID-19 vaccination in support of Biden administration's vaccination efforts.

    Philips (PHG) Recalls CPAP, Ventilators Used for Sleep Apnea

    by Zacks Equity Research

    Philips (PHG) is recalling some Bi-Level PAP, CPAP, and mechanical ventilator devices in the United States due to health risks.

    Veeva (VEEV) Customer Intelligence Platform Reaches New Areas

    by Zacks Equity Research

    Veeva Link's expansion across 11 new therapeutic areas to drive engagement for Veeva's (VEEV) partner companies with key experts.

    Tandem (TNDM) Presents Data Backing Control-IQ Technology

    by Zacks Equity Research

    Data presented at the ATTD conference demonstrates Tandem Diabetes Care's (TNDM) Control-IQ technology's ability to make a positive and sustained impact on diabetes care.

    Bruker (BRKR) FluoroType Assay Detects New SARS-CoV-2 Variants

    by Zacks Equity Research

    Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.

    Medtronic's (MDT) STROKE AF Trial Outcome Backs ICM Progress

    by Zacks Equity Research

    STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.

    Syneos' (SYNH) New Patient Consortium to Drive Innovation

    by Zacks Equity Research

    Syneos' (SYNH) Patient Voice Consortium incorporates patient perspective across wide range of communities to guide product development lifecycle.

    IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm

    by Zacks Equity Research

    The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.

    PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension

    by Zacks Equity Research

    PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.

    Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows

    by Zacks Equity Research

    The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.

    QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS

    by Zacks Equity Research

    QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.